BTM signed the exclusive rights to promote Pellefeel & PLTenus in China, entering the field of Orthopedics and Wound Care

BTM signed agreement with Taiwan TCM Biotech Corp. for the exclusive rights to promote Pellefeel Mask Pressure Relief Pad and PLTenus Platelet-rich Plasma Kits in China in December, 2019, which marked the start of BTM‘s efforts to commercialize innovative products in China.

With the aggravation of aging population and the subsequent soaring number of chronic wound patients, the market demand for advanced wound dressing in China will continue to grow. While Covid-19 pandemic is pushing for the improvement of ICU facilities, doctors and patients are now expecting more and better products of pressure ulcer prevention and treatment from the market. Based on the theory of moist wound healing, Pellefeel wound care products use new materials of high-end patented technologies and focus on the prevention and treatment of acute and chronic wounds with the advantages of shortening the healing period, improving the wound healing, alleviating the pain of patients and reducing the labor intensity of medical personnel.

As a result of a rising number of people suffering from osteoarthritis and bone-related diseases caused by the aging population, increasing needs of cosmetic surgery, the broadening application of PRP therapy and the continuous R&D for new technologies within the past decade, China has become the fastest growing market for PRP in the world. PRP has been widely used in Stomatology, Ophthalmology, Orthopedics, Dermatology, Plastics & Cosmetics and other clinical fields. PLTenus PRP Kit is manufactured with unique patented technologies, which can provide P-PRP with higher concentration and purity for clinical use. PLTenus PRP kit can reduce inflammatory responses more effectively and accelerate tissue’s regeneration and repair. With convenient preparation, high cost-effectiveness and low risk of infection, PLTenus PRP kit Provides better treatment option to the clinic.